Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
20028	Pegylated liposomal irinotecan	Onivyde®	For the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.	Assessment process complete	12th November 2021
-	Pembrolizumab	Keytruda®	For the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.	Rapid Review Complete	27th July 2018
-	Pembrolizumab	Keytruda®	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.	Assessment process complete	15th August 2019
-	Pembrolizumab	Keytruda®	In combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of the first-line treatment of metastatic squamous non-small cell lung carcinoma.	Rapid Review Complete	26th March 2019
22042	Pembrolizumab	Keytruda®	Is indicated for the adjuvant treatment of adults and adolescent (≥12 years) with stage IIB or IIC melanoma following complete resection.	NCPE assessment ongoing	5th April 2024
23058	Pembrolizumab	Keytruda®	Pembrolizumab as monotherapy for the treatment of mismatch repair deficient or microsatellite instability-high tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.	Rapid Review Complete	25th October 2023
-	Pembrolizumab	Keytruda®	As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.	Assessment Process Complete	15th May 2020
22026	Pembrolizumab	Keytruda®	Is indicated as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	NCPE assessment ongoing	18th April 2024
-	Pembrolizumab	Keytruda®	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.	Rapid Review Complete	22nd December 2017
21013	Pembrolizumab	Keytruda®	For the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.	Rapid Review Complete	14th May 2021
21002	Pembrolizumab	Keytruda®	Is indicated as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.	NCPE Assessment Process Complete	13th October 2022
19051	Pembrolizumab	Keytruda®	Is indicated as monotherapy or in combination with platinum and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a combined positive score.	Assessment Process Complete	18th May 2021
21059	Pembrolizumab	Keytruda®	In combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) in adults whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 and who have not received prior chemotherapy for metastatic disease.	Rapid Review Complete	13th January 2022
22027	Pembrolizumab	Keytruda®	Is indicated in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	NCPE Assessment Process Complete	18th December 2023
-	Pembrolizumab	Keytruda®	For the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.	Assessment Process Complete	10th October 2017
-	Pembrolizumab	Keytruda®	Is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.	Assessment Process Complete	29th May 2018
21032	Pembrolizumab	Keytruda®	In combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10.	NCPE Assessment Process Complete	6th July 2023
22041	Pembrolizumab	Keytruda®	Is indicated in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1.	Rapid Review Complete	6th July 2022
-	Pembrolizumab	Keytruda®	For the first line treatment of unresectable or advanced metastatic melanoma in adults.	Assessment Process Complete	9th February 2016
-	Pembrolizumab	Keytruda®	For the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.	Assessment Process Complete	9th February 2016
-	Pembrolizumab	Keytruda®	As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.	Assessment process complete	25th March 2019
19027	Pembrolizumab	Keytruda®	In combination with axitinib (Inlyta®), is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.	Assessment Process Complete	21st December 2020
22006	Pembrolizumab	Keytruda®	In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.	NCPE Assessment Process Complete	18th December 2023
23056	Pembrolizumab	Keytruda®	Pembrolizumab (Keytruda®) In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1.	Awaiting full HTA submission from Applicant	5th December 2023
23070	Pembrolizumab	Keytruda®	Pembrolizumab (Keytruda®) is indicated in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1	Rapid Review Complete	18th December 2023
23078	Pembrolizumab	Keytruda®	Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy*.	Rapid Review Complete	24th January 2024
-	Pentosan Polysulfate Sodium [PPS]	Elmiron®	For the treatment of bladder pain syndrome (BPS) characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.	Rapid Review Complete	24th January 2019
-	Perampanel	Fycompa®	For treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.	Rapid Review Complete	31st July 2013
-	Pertuzumab	Perjeta®	Is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.	Assessment Process Complete	31st January 2019
-	Pertuzumab	Perjeta®	The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.	Assessment Process Complete	28th August 2013
-	Pertuzumab	Perjeta®	Is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.	Assessment Process Complete	11th May 2016
20053	Pertuzumab and trastuzumab	Phesgo®	For the treatment of Early breast cancer and Metastatic breast cancer	Rapid Review Complete	6th January 2021
-	Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride	Fydrane®	Is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.	Rapid Review Complete	20th December 2016
-	Piperaquine tetraphosphate/dihidroartemisinin	Eurartesim®	For uncomplicated malaria caused by the Plasmodium falciparum parasite	Rapid Review Complete	28th May 2012
-	Pirfenidone	Esbriet®	For the treatment of mild to moderate idiopathic pulmonary fibrosis.	Assessment Process Complete	20th March 2013
-	Pitavastatin	Livazo®	Is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.	Rapid Review Complete	29th December 2010
-	Pitolisant hydrochloride	Wakix®	For the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.	Rapid Review Complete	15th June 2017
23054	Pitolisant hydrochloride	Wakix®	Pitolisant hydrochloride (Wakix®) is indicated in adults, adolescents, and children aged 6 years and older for the treatment of narcolepsy with or without cataplexy	Rapid Review Complete	4th October 2023
-	Pixantrone	Pixuvri®	Is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).	Rapid Review Complete	20th March 2015
19052	Polatuzumab vedotin	Polivy®	In combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).	Assessment Process Complete	16th February 2021
22043	Polatuzumab vedotin	Polivy®	In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).	NCPE Assessment Process Complete	5th December 2023
-	Polynuclear iron(III)-oxyhydroxide (pn-FeOOH)	Velphoro®	Is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Rapid Review	Rapid Review Complete	8th October 2014
-	Pomalidomide	Imnovid®)	In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	Assessment Process Complete	13th March 2015
22016	Pomalidomide	Imnovid®	In combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Rapid Review Complete	5th May 2022
-	Ponatinib	Iclusig®	Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	Assessment Process Complete	4th January 2016
21036	Ponesimod	Ponvory®	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Rapid Review Complete	8th October 2021
-	Prasugrel	Efient®	For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.	Assessment Process Complete	1st February 2010
-	Pregabalin	Lyrica®	For the treatment of Generalised Anxiety Disorder.	Full HTA Assessment	15th December 2014
-	Pregabalin	Lyrica®	For the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.	Full HTA Assessment	12th June 2015
-	Progesterone (micronised)	Utrogestan®	Progesterone (micronised) is indicated in women for supplementation of the luteal phase during ART cycles.	Rapid Review Complete	20th November 2019